Navigation Links
Transdel Pharmaceuticals to Present at Cowen and Company's 28th Annual Health Care Conference
Date:3/18/2008

LA JOLLA, Calif., March 18 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically administered medications, today announced that Dr. Juliet Singh, President and Chief Executive Officer, will present at Cowen and Company's 28th Annual Health Care Conference on Thursday, March 20, 2008 at 10:15 a.m. Eastern Time at The Marriott Copley Place in Boston, MA.

Dr. Singh will discuss the Company's business developments to date including the recent submission of the Phase 3 clinical study of Ketotransdel(TM) to the FDA.

Interested parties can access a live audio webcast and accompanying slide presentation via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.transdelpharma.com. An archived presentation will be available on the Web site for 30 days.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) is a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically delivered medications. The Company's lead topical drug, Ketotransdel(TM), utilizes the Company's innovative patented proprietary Transdel(TM) cream formulation technology to facilitate the passage of ketoprofen, an NSAID, through the skin barrier to reach targeted underlying tissue where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas.

Safe Harbor Statement

The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

Contact:

John Lomoro

Chief Financial Officer

Transdel Pharmaceuticals, Inc.

858-457-5300


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
2. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
3. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
4. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
5. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
6. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
7. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
9. Drinking Water Association Discusses Pharmaceuticals in Water
10. Genesis Pharmaceuticals Changes Auditors
11. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health Advocate ... Solutions Series of webinars will start January 31 with a session about understanding ... current health and benefits topics, including employee engagement, pricing transparency, population health and ...
(Date:1/24/2017)... ... 24, 2017 , ... This Saturday, January 28, the BCFA presents more than ... by Alabama Symphony Orchestra musicians Yifan Zhou, Mara McClain & Sarah Nordlund Dennis. Local ... exhibitors offer a look at Chinese games, crafts & more. Festivities begin at 11:00 ...
(Date:1/24/2017)... ... January 24, 2017 , ... The NewKILO JRP, a three-year project ... co-funded by the European Union (EU), was completed in May 2015. The future definition ... maintained and used in air, which presents some challenges to establishing traceability to the ...
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com recently gave a ... premenstrual syndrome, or PMS . , Most women of child-bearing age will experience ... constipation, irritability, headaches, fatigue, and other discomfort. For some women, the effects ...
(Date:1/24/2017)... ... ... “Mysteries Revealed On Speaking In Tongues”: an engaging and dynamic study on what ... On Speaking In Tongues” is the creation of published author, Tina Jackson, the editor, ... , “We need to partner with Jesus and be the voice piece to ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... -- Trifecta Clinical , a leading global provider ... Ward to Vice President of Commercial Operations.  Rick ... the promotion of Ericka Atkinson to Vice ... joins Trifecta from Greenphire where he was Vice President ... positions within the healthcare industry throughout his career.  "Rick ...
(Date:1/24/2017)... Results show Gamma Knife spares normal brain tissue ... Elekta (EKTA-B.ST) today announced new data demonstrating ... a higher radiation dose compared to linear accelerator (linac)-based delivery ... complex brain tumors, were published in the Journal ... ...
(Date:1/24/2017)... , January 24, 2017 www.Financialbuzz.com ... growing industries in the United States ... in 2016. In addition, Proposition 64, the California Cannabis Legalization ... 42.87% against on November 8, 2016. This outcome means that ... use and to grow a certain amount of cannabis for ...
Breaking Medicine Technology: